A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Fiona Blackhall; A. R. Clamp; F. H. Blackball; P. Vasey; M. Soukop; R. Coleman; G. Halbert; L. Robson; G. C. Jayson

doi:10.1038/sj.bjc.6601285

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Fiona Blackhall, A. R. Clamp, F. H. Blackball, P. Vasey, M. Soukop, R. Coleman, G. Halbert, L. Robson, G. C. Jayson

Research output: Contribution to journal › Article › peer-review

Abstract

Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia. © 2003 Cancer Research UK.

Original language	English
Pages (from-to)	1152-1154
Number of pages	2
Journal	British Journal of Cancer
Volume	89
Issue number	7
DOIs	https://doi.org/10.1038/sj.bjc.6601285
Publication status	Published - 6 Oct 2003

Keywords

Bryostatin-1
Clinical trial
Ovarian cancer
Protein kinase C

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6601285

Cite this

@article{cf960f7a34024824ad57d5134cb74376,

title = "A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma",

abstract = "Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia. {\textcopyright} 2003 Cancer Research UK.",

keywords = "Bryostatin-1, Clinical trial, Ovarian cancer, Protein kinase C",

author = "Fiona Blackhall and Clamp, {A. R.} and Blackball, {F. H.} and P. Vasey and M. Soukop and R. Coleman and G. Halbert and L. Robson and Jayson, {G. C.}",

year = "2003",

month = oct,

day = "6",

doi = "10.1038/sj.bjc.6601285",

language = "English",

volume = "89",

pages = "1152--1154",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

AU - Blackhall, Fiona

AU - Clamp, A. R.

AU - Blackball, F. H.

AU - Vasey, P.

AU - Soukop, M.

AU - Coleman, R.

AU - Halbert, G.

AU - Robson, L.

AU - Jayson, G. C.

PY - 2003/10/6

Y1 - 2003/10/6

N2 - Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia. © 2003 Cancer Research UK.

AB - Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia. © 2003 Cancer Research UK.

KW - Bryostatin-1

KW - Clinical trial

KW - Ovarian cancer

KW - Protein kinase C

U2 - 10.1038/sj.bjc.6601285

DO - 10.1038/sj.bjc.6601285

M3 - Article

SN - 0007-0920

VL - 89

SP - 1152

EP - 1154

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this